Cargando…

Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies

Mechanistic modeling of signaling pathways mediating patient‐specific response to therapy can help to unveil resistance mechanisms and improve therapeutic strategies. Yet, creating such models for patients, in particular for solid malignancies, is challenging. A major hurdle to build these models is...

Descripción completa

Detalles Bibliográficos
Autores principales: Eduati, Federica, Jaaks, Patricia, Wappler, Jessica, Cramer, Thorsten, Merten, Christoph A, Garnett, Mathew J, Saez‐Rodriguez, Julio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029724/
https://www.ncbi.nlm.nih.gov/pubmed/32073727
http://dx.doi.org/10.15252/msb.20188664
_version_ 1783499226506854400
author Eduati, Federica
Jaaks, Patricia
Wappler, Jessica
Cramer, Thorsten
Merten, Christoph A
Garnett, Mathew J
Saez‐Rodriguez, Julio
author_facet Eduati, Federica
Jaaks, Patricia
Wappler, Jessica
Cramer, Thorsten
Merten, Christoph A
Garnett, Mathew J
Saez‐Rodriguez, Julio
author_sort Eduati, Federica
collection PubMed
description Mechanistic modeling of signaling pathways mediating patient‐specific response to therapy can help to unveil resistance mechanisms and improve therapeutic strategies. Yet, creating such models for patients, in particular for solid malignancies, is challenging. A major hurdle to build these models is the limited material available that precludes the generation of large‐scale perturbation data. Here, we present an approach that couples ex vivo high‐throughput screenings of cancer biopsies using microfluidics with logic‐based modeling to generate patient‐specific dynamic models of extrinsic and intrinsic apoptosis signaling pathways. We used the resulting models to investigate heterogeneity in pancreatic cancer patients, showing dissimilarities especially in the PI3K‐Akt pathway. Variation in model parameters reflected well the different tumor stages. Finally, we used our dynamic models to efficaciously predict new personalized combinatorial treatments. Our results suggest that our combination of microfluidic experiments and mathematical model can be a novel tool toward cancer precision medicine.
format Online
Article
Text
id pubmed-7029724
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70297242020-02-25 Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies Eduati, Federica Jaaks, Patricia Wappler, Jessica Cramer, Thorsten Merten, Christoph A Garnett, Mathew J Saez‐Rodriguez, Julio Mol Syst Biol Articles Mechanistic modeling of signaling pathways mediating patient‐specific response to therapy can help to unveil resistance mechanisms and improve therapeutic strategies. Yet, creating such models for patients, in particular for solid malignancies, is challenging. A major hurdle to build these models is the limited material available that precludes the generation of large‐scale perturbation data. Here, we present an approach that couples ex vivo high‐throughput screenings of cancer biopsies using microfluidics with logic‐based modeling to generate patient‐specific dynamic models of extrinsic and intrinsic apoptosis signaling pathways. We used the resulting models to investigate heterogeneity in pancreatic cancer patients, showing dissimilarities especially in the PI3K‐Akt pathway. Variation in model parameters reflected well the different tumor stages. Finally, we used our dynamic models to efficaciously predict new personalized combinatorial treatments. Our results suggest that our combination of microfluidic experiments and mathematical model can be a novel tool toward cancer precision medicine. John Wiley and Sons Inc. 2020-02-19 /pmc/articles/PMC7029724/ /pubmed/32073727 http://dx.doi.org/10.15252/msb.20188664 Text en © 2020 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Articles
Eduati, Federica
Jaaks, Patricia
Wappler, Jessica
Cramer, Thorsten
Merten, Christoph A
Garnett, Mathew J
Saez‐Rodriguez, Julio
Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies
title Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies
title_full Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies
title_fullStr Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies
title_full_unstemmed Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies
title_short Patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies
title_sort patient‐specific logic models of signaling pathways from screenings on cancer biopsies to prioritize personalized combination therapies
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029724/
https://www.ncbi.nlm.nih.gov/pubmed/32073727
http://dx.doi.org/10.15252/msb.20188664
work_keys_str_mv AT eduatifederica patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies
AT jaakspatricia patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies
AT wapplerjessica patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies
AT cramerthorsten patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies
AT mertenchristopha patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies
AT garnettmathewj patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies
AT saezrodriguezjulio patientspecificlogicmodelsofsignalingpathwaysfromscreeningsoncancerbiopsiestoprioritizepersonalizedcombinationtherapies